#pharma deals

All articles tagged with "pharma deals"

ASCO Abstract Drop Signals a New Round in Oncology’s Data Race

Even with limited details in the supplied text, the release of regular ASCO abstracts appears to have focused attention on several contested oncology areas, underscoring how conference data now drives pharmaceutical deal

Key Takeaways

ASCO’s abstract drop is highlighting several high-stakes oncology races.
The supplied text points to interest in VEGF bispecifics, TROP2 ADCs and post-Ibrance strategies.

DT Editorial Team·May 24, 2026·via endpoints.news

Late-Quarter Biotech Dealmaking and Trial Setbacks Show a Sector Still Repricing Risk

A weekly Endpoints roundup points to a biotech market closing the quarter with bolt-on acquisitions, obesity-program volatility, and a Sanofi partnership in T-cell engager research.

Key Takeaways

The supplied roundup highlights bolt-on deals near the end of Q1 2026.
It references a Wave decline tied to obesity data.

DT Editorial Team·Mar 29, 2026·via endpoints.news

Insilico and Lilly Put Another Big Number on AI Drugmaking

Candidate metadata indicates Eli Lilly has signed a commercialization deal with Insilico Medicine worth $115 million upfront and up to roughly $2.75 billion in milestone payments.

Key Takeaways

Candidate metadata says Lilly signed a commercialization deal with Insilico Medicine.
The agreement includes $115 million upfront.

DT Editorial Team·Mar 29, 2026·via statnews.com